Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LHRHa · 1 trial · 1 indication
ppMPFS is defined as the appearance of at least one new PSMA-PET-positive distant lesion compared with the previous scan as assessed by blinded independent central review (BICR) or death.
| Arm | Type | Description |
|---|---|---|
| Interventional Cohort (Group 1): RT+ LHRHa | ACTIVE_COMPARATOR | Participants will receive radiotherapy (RT) which is defined as prostate-bed plus pelvic lymph node salvage external-beam radiotherapy with or without optional stereotactic body radiation therapy (SBRT), along with a luteinizing hormone-releasing hormone agonist (LHRHa) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12, or as a 6-monthly depot preparation within 3 days after randomization. |
| Interventional Cohort (Group 2): RT+LHRHa + Apalutamide | EXPERIMENTAL | Participants will receive prostate-bed plus pelvic lymph node salvage external-beam radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), along with a LHRHa as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12, or as a 6-monthly depot preparation within 3 days after randomization. Participants will also receive 240 milligram (mg) of apalutamide starting within 3 days after randomization as film-coated tablets, to be swallowed whole and together once daily with or without food, for a period of 180 Days. |
| Observational Cohort(Group3) PSMA-PET Negative Participants | NO_INTERVENTION | Enrollment into this cohort will be stopped further. Participants who were PSMA-PET-negative at screening and were already enrolled in the Observational Cohort will continue in this cohort. Data collected in the course of routine clinical practice during this period will include clinical evaluations, disease progression, therapies administered as per standard-of-care at the study-sites and survival status. For Observational Cohort, information will be entered into the electronic case report form (eCRF) from the medical records at least twice a year. The use of any medicinal product(s) for the treatment and management of participants will be at discretion of the treating physician. |
| Name | Type | Description |
|---|---|---|
| Radiotherapy | RADIATION | Participants will receive radiotherapy (RT) with or without optional stereotactic body radiation therapy (SBRT), which will start within 4 weeks after randomization. |
| LHRHa | DRUG | Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the end of Week 12 or as a 6-monthly depot preparation within 3 days after randomization. |
| Apalutamide | DRUG | Participants will receive therapeutic dose of apalutamide 240 mg once daily for 180 Days. |
Inclusion Criteria: * Histologically confirmed adenocarcinoma of the prostate * Previously treated with radical prostatectomy with or without lymph node dissection and either: a) for biochemical recurrence after radical prostatectomy (RP): any post-operative prostate-specific antigen (PSA) measurem...
LHRHa is a small molecule being studied for the treatment of prostatic neoplasms, specifically in high-risk patients with hormone-sensitive prostate cancer. It is used in combination with radiotherapy and apalutamide in an active clinical trial. The drug is currently in Phase 3 development and is not yet approved.
LHRHa is being developed by Johnson & Johnson, a company publicly traded under the ticker JNJ. The drug is currently in Phase 3 clinical development for the treatment of prostatic neoplasms. Johnson & Johnson is conducting a randomized, active-controlled trial to evaluate the drug in combination with other therapies.
LHRHa is in Phase 3 clinical development. It is being studied in an active, not recruiting trial for high-risk patients with hormone-sensitive prostate cancer. The drug is investigational and has not yet received FDA approval. The Phase 3 trial is randomized and active-controlled, with a planned enrollment of 691 participants.
LHRHa is being evaluated in a single Phase 3 clinical trial with the identifier NCT04557059. The trial is titled 'A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer.' It is active but not recruiting, with a target enrollment of 691 male participants aged 18 years and older.
LHRHa refers to an LHRH agonist, a type of hormone therapy used in prostate cancer treatment. In the clinical trial NCT04557059, LHRHa is combined with radiotherapy and apalutamide for high-risk patients with hormone-sensitive prostate cancer. The drug is being developed by Johnson & Johnson and is currently in Phase 3 testing.